Dolichol-phosphate-mannose-3 (DPM3)/prostin-1 is a novel phospholipase C-gamma regulated gene negatively associated with prostate tumor invasion.
The most ominous development in tumor progression is the transition to an invasive and metastatic phenotype. Little is known, however, about the molecular alterations that cause a tumor to become invasive. In view of this, we have used microarray expression analysis to evaluate the expression profiles of a unique panel of human DU145 prostate cancer sublines that vary in their invasive potential. The three DU145 sublines expressed epidermal growth factor (EGF) receptors that differed in their ability to activate phospholipase C-gamma (PLC gamma). Three-way analyses yielded 11 genes out of 4608 genes screened that associated directly or inversely with invasive potential. The gene whose expression correlated most strongly with lack of invasion was identified as a potential invasion suppressor and called prostin-1. Pharmacological inhibition of PLC gamma (U73122) confirmed that PLC gamma signaling suppressed prostin-1 in that U73122 treatment caused induction of prostin-1 in PLC gamma competent cells. The prostin-1 gene, conserved through phylogeny, is induced by androgen in LNCaP cells and encodes a 92 amino acid protein. The protein shares no extensive homologies with other known genes, yet was recently identified as a small stabilizer subunit of the dolichol-phosphate-mannose (DPM) synthase complex. That DPM3/prostin-1 might suppress tumor progression was supported by the finding that exogenous expression in COS cells leads to apoptosis. These findings support the use of model cell lines to identify putative tumor suppressors and promoters.
Manos
E J
EJ
Division of Molecular Pharmacology, Hunstman Cancer Institute, University of Utah, Salt Lake City, Utah, 84112, USA.
Kim
M L
ML
Kassis
J
J
Chang
P Y
PY
Wells
A
A
Jones
D A
DA
D001483:Base Sequence; D004789:Enzyme Activation / Q000235:genetics; D004791:Enzyme Inhibitors / Q000494:pharmacology; D066246:ErbB Receptors / Q000235:genetics; D004963:Estrenes / Q000494:pharmacology; D016147:Genes, Tumor Suppressor / Q000235:genetics*; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology*; D008297:Male; D008364:Mannosyltransferases; D008565:Membrane Proteins / Q000737:chemistry / Q000235:genetics*; D008969:Molecular Sequence Data; D009361:Neoplasm Invasiveness; D020411:Oligonucleotide Array Sequence Analysis; D051966:Phospholipase C gamma; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000473:pathology; D011760:Pyrrolidinones / Q000494:pharmacology; D014407:Tumor Cells, Cultured; D010738:Type C Phospholipases / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology*
D004791:Enzyme Inhibitors; D004963:Estrenes; D007527:Isoenzymes; D008565:Membrane Proteins; D011760:Pyrrolidinones; C060229:1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione; D008364:Mannosyltransferases; C429687:DPM3 protein, human; D066246:ErbB Receptors; D010738:Type C Phospholipases; D051966:Phospholipase C gamma